• Natera’s third-quarter 2026 net loss narrowed 32% year over year to $59.91 million.
• Total revenues rose 34% year over year to $794 million, driven by higher volumes and improved average selling prices.
• Oncology tests processed jumped 61% year over year to approximately 339,500 in the quarter.
• The company raised its 2026 total revenues guidance to $3.01 billion–$3.04 billion and expects positive cash flow.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051605BIZWIRE_USPR_____20261105_BW041347) on November 05, 2026, and is solely responsible for the information contained therein.